Lionheart Ventures is an early-stage venture capital firm specializing in artificial intelligence and frontier mental-health technologies. Its mental-health practice backs psychedelic medicines, neuromodulation and other approaches intended to improve care, while its AI practice invests in technologies that support human agency, resilience and safety. The firm evaluates both commercial opportunity and the potential effects of transformative technology on human flourishing. Its published team combines founders and operators with neuroscience, clinical-development, regulatory, intellectual-property and AI-safety expertise, supporting companies through investment, technical advice and founder networks.
Founded
2019
Type
Venture capital
Funds3
Lionheart AI I, L.P.——
Lionheart’s AI venture-capital vehicle, managed through Lionheart AI I GP, LLC and identified in the adviser’s current regulatory filing. First sale is reported as May 8, 2024. Exact final corpus and public fund-announcement date are unverified.
Lionheart Ventures II, L.P.——
Lionheart’s second numbered venture-capital vehicle, legally identified under Lionheart Ventures II GP, LLC in its current adviser filing. The firm specializes in AI and frontier mental-health technologies; exact final fund size and public announcement date are undisclosed in the verified primary evidence.
Lionheart Ventures II-A, L.P.—$10M
A legally distinct Lionheart venture-capital vehicle managed by Lionheart Ventures II GP, LLC. Its April 2026 Form D amendment reports USD10 million of cumulative fund interests sold to one investor, with first sale on April 20, 2025 and an indefinite offering. This is a regulatory sales snapshot, not a claimed final close or standalone strategy allocation.
Piramidal$6M · 2024-08-21
Y Combinator
Reconnect Labs